-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu (600079.SH): Midazolam injections obtained marketing approval from the UK Medicines and Health Products Regulatory Authority (MHRA)

Zhitongcaijing·08/20/2026 07:57:04
Listen to the news

Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Recently, the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) received a marketing license approval letter for midazolam injections approved and issued by the UK Medicines and Health Products Administration (MHRA).

Midazolam injections have obtained marketing approval from the UK Medicines and Health Products Authority (MHRA). The approved indications are: (1) sober sedation before, after and during diagnostic or therapeutic operations (whether combined with local anesthesia or not); (2) preoperative use before induction of anesthesia in adults, anesthesia induction, and use in combination with other anesthetics as sedatives; preoperative use before induction of anesthesia in children; (3) sedation in intensive care units (ICU).